The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Ameridose, LLC, of Westborough, MA, the add-mixing sister company of the Framingham-based New England Compounding Center (NECC), has announced a recall of all of its products on the heels of the closing and investigations into the NECC. The NECC is believed to be responsible for compounding and shipping contaminated steroid injectable medications to at least 23 states causing 29 deaths and sickening more than 400 people. According to a recent New York Times article, although the companies are “legally distinct” from one another, they are owned by some of the same people. Ameridose, a major supplier of sterile injectable medications to hospitals throughout the US has stipulated that this product recall is “out of an abundance of caution.” Ameridose produces and sells more than 2,200 blended drugs including anesthetics, antibiotics, anticoagulants, antidepressants, pain killers and tranquilizers. The Food and Drug Administration (FDA) has notified Ameridose of its concern about some of their “sterility assurances” and that the FDA will be “seeking improvements in Ameridose’s sterility testing process.” The list of drug products being recalled is posted on the Ameridose company website: http://www.ameridose.com [One should note that the Ameridose product list includes Prednisolone Oral Solution, and Prednisolone Sodium Phosphate Oral Solution in oral syringes. NECC distributed methylprednisolone acetate which was contaminated and is believed to have caused fungal meningitis among other infections in patients in which the drug was injected.] Hospitals have already reported difficulty in obtaining these drugs and their recall will not ameliorate current drug shortages.

For a list of recalled Ameridose products, visit: http://cdn-ecomm.dreamingcode.com/public/195/documents/Version-20121031152001-Documents-195-1704-1.pdf

Comments for this article are closed.